“Semaglutide is very effective for weight loss,” says Dr. Saunders. In fact, a 2021 phase 3 clinical trial found that 2.4 ...

According to research, semaglutide is administered subcutaneously once a week with dosage guidelines that can vary between 1.7mg per week and 2.4mg per week, helping patients achieve significant ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

UPDATED // Based on the STEP clinical trial results, the FDA has approved a 2.4 mg/week subcutaneous dose of the GLP-1 receptor agonist semaglutide (Wegovy, Novo Nordisk) for weight loss.

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

The phase 3a STEP 1 trial that investigated the use of semaglutide (Novo Nordisk), a glucagon-like peptide-1 (GLP-1) agonist, for weight loss is aptly named, some say. "In sum, we have a long way ...

Taking semaglutide may lead to a slight increase in heart rate — typically by two to three beats per minute, based on trials sponsored by Novo Nordisk using 0.5 and 1 mg doses of semaglutide.

N Engl J Med. 2016;375 (19):1834-1844. doi: 10.1056/NEJMoa1607141. Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 [press release].

The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Participants received an escalating dose of semaglutide or placebo for the first 16 weeks. The 2.4 mg of semaglutide was then administered for 1 year, ending at week 68 of the trial.

Columnist Teri Sforza writes that studies have found that the popular weight-loss and diabetes drugs reduced alcohol intake, ...